Comparing the current results to its competitors, Silk Road Medical Inc reported Revenue increase in the 2 quarter 2022 by 25.39 % year on year. The sales growth was above Silk Road Medical Inc 's competitors' average revenue growth of 2.86 %, achieved in the same quarter.
Silk Road Medical Inc , slower than the average decrease reported by the company's competitors of -7.02 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -7.02 %
Silk Road Medical Inc 's Comment on Competition and Industry Peers
The competitive landscape for transcarotid artery revascularization (TCAR) includes companies developing TCAR-specific products such as Contego Medical Inc. and InspireMD, Inc. Additional competitors offer endovascular products applicable to both carotid artery stenting (CAS) and TCAR, including Abbott Laboratories, Boston Scientific Corporation, Cordis Corporation, Medtronic plc, and Cook Medical Inc. Competition also encompasses personnel recruitment. Key competitive factors include patient outcomes, patient experience, physician acceptance, ease of use, recovery time, economic benefits, pricing, reimbursement availability, and the strength of clinical evidence. Furthermore, competition exists from manufacturers of medications used in carotid artery disease management, such as aspirin and statins. These pharmaceutical companies benefit from established treatment protocols, relationships with general practitioners, greater name recognition, and larger sales and marketing resources.
Meihua International Medical Technologies Co Ltd Share Performance
-81.83%
This Quarter
Meihua International Medical Technologies Co Ltd
Profile
Meihua International Medical Technologies Co. Limi operates on a business model focused on the development and distribution of medical technologies and solutions. The company aims to deliver innovative and quality medical equipment to healthcare providers and institutions globally. By leveraging their expertise and partnerships, Meihua strives to enhance healthcare outcomes and contribute to the advancement of medical technology.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Lemaitre Vascular Inc is a medical device company specializing in the design, development, and distribution of innovative medical devices for the treatment of peripheral vascular disease. Their business model revolves around creating and manufacturing high-quality products that address specific needs in the field of vascular surgery. They leverage a combination of direct sales, distribution partnerships, and ongoing research and development efforts to effectively reach healthcare professionals and provide comprehensive solutions for patients.
Livanova Plc is a global medical technology company that focuses on developing and delivering innovative solutions for patients with cardiovascular diseases and neuropsychiatric disorders. Through their diverse portfolio, they offer products and therapies that encompass surgical heart valves, cardiac rhythm management, and neuromodulation. Livanova adopts a patient-centric approach, collaborating with healthcare professionals to improve patient outcomes and enhance quality of life.
Sources:
Silk Road Medical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Silk Road Medical Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
